Colorectal Cancer Metastatic
Conditions
Keywords
Colorectal liver metastasis, Hepatic Artery Infusion Chemotherapy, RAS-mutation, Systemic Chemotherapy, FOLFOX, FOLFOXIRI, Initially unresectable colon cancer
Brief summary
This prospective, randomized, controlled clinical study aims to evaluate the objective remission rate of FOLFOX hepatic artery infusion chemotherapy (HAI) in combination with systemic irinotecan with or without bevacizumab versus systemic intravenous FOLFOXIRI with or without bevacizumab in initially unresectable RAS-mutated colorectal cancer patients with liver metastases.
Detailed description
PRIMARY OBJECTIVES: The goal of this prospective, randomized, controlled clinical trial is to evaluate the objective remission rate (ORR) of FOLFOX hepatic artery infusion chemotherapy (HAI) in combination with irinotecan with or without bevacizumab systemic intravenous chemotherapy versus systemic intravenous FOLFOXIRI with or without bevacizumab in initially unresectable RAS-mutated colorectal cancer patients with liver metastases. SECONDARY OBJECTIVES: To assess and compare the depth of response (DpR), R0 surgical resection rate, No evidence of disease (NED) rate, progression-free survival (PFS), overall survival (OS), recurrence-free survival (RFS) in resectable patients and safety (chemotherapy-related adverse events, catheterization-related adverse events, surgical complications, etc.) between the two intervention groups. OUTLINE: Patients in the HAI group receive FOLFOX via hepatic artery infusion chemotherapy plus intravenous irinotecan with or without bevacizumab every 14 days, while patients in the systemic group receive intravenous FOLFOXIRI regimen with or without bevacizumab every 14 days. Patients will receive a maximum of 12 cycles in total (before and after surgery) unless there is disease progression, unacceptable toxicity, or if the patient withdraws from the study.
Interventions
DRUGDexamethasone
25mg via HAI (Pre-chemotherapy)
DRUGAnisodamine
10 mg via HAI (Pre-chemotherapy)
DRUGOxaliplatin
85 mg/m2 via HAI over 3 hours
DRUGLeucovorin
200 mg/m2 via HAI
DRUGFluorouracil
400 mg/m2 via HAI and 2.4g/m2 via HAI over 48 hours
DRUGIrinotecan
150 mg/m2 intravenously
DRUGBevacizumab
5 mg/kg intravenously
Sponsors
Sun Yat-sen University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Histologically confirmed colorectal adenocarcinoma 2. Imaging or pathological confirmation of liver metastases 3. The multidisciplinary team determined that the liver metastases were unresectable, defined as (i) ≥5 metastases; (ii) inability to perform R0 resection; (iii) insufficient volume of liver expected to remain after resection; (iv) failure to preserve all 3 hepatic veins after resection, failure to ensure that blood flow to and from the liver and bile ducts can be preserved, and failure to preserve 2 adjacent liver segments. If any of the above criteria are met, it can be considered as initially unresectable liver metastases. 4. Patients with mutated RAS and BrafV600E 5. No previous treatment for liver metastases, including chemotherapy, surgery, radiotherapy, transarterial chemoembolization (TACE) and targeted therapy 6. No extrahepatic metastases confirmed by CT, MRI, or PET/CT (if necessary) (consider enrollment if there is a lung or lymph node lesion less than 10 mm and metastases are difficult to identify) 7. Normal hematological function (platelets \>90×109/L; white blood cells \>3×109/L; neutrophils \>1.5×109/L) 8. Serum bilirubin ≤ 1.5 times the upper limit of normal value (ULN), transaminases ≤ 5 times ULN 9. No ascites, normal coagulation function, albumin ≥35g/L 10. Liver function Child-Push grade A 11. Serum creatinine less than upper limit of normal (ULN) or calculated creatinine clearance \>50 ml/min (using Cockcroft-Gault formula) 12. ECOG score 0-1 13. Life expectancy \> 3 months 14. Signed written informed consent
Exclusion criteria
(Patients meeting any of the following criteria will be excluded from the study): 1. Presence of any extrahepatic metastases and/or primary tumor not amenable to radical surgical resection 2. Development of liver metastases within 1 year after completion of adjuvant chemotherapy with FOLFOX or XELOX 3. Severe arterial embolism or ascites 4. Bleeding tendency or coagulation disorder 5. Hypertensive crisis or hypertensive encephalopathy 6. Severe uncontrolled systemic complications such as infections or diabetes mellitus 7. Clinically significant cardiovascular disease such as cerebrovascular accident (within 6 months prior to enrollment), myocardial infarction (within 6 months prior to enrollment), uncontrolled hypertension despite appropriate medication, unstable angina pectoris, congestive heart failure (NYHA class 2-4), arrhythmias requiring medication 8. History or physical examination revealing a central nervous system disease (e.g., primary brain tumor, epilepsy not manageable by standard therapy, presence of brain metastases, or history of stroke) 9. Previous malignancy within the last 5 years (except post-radical surgery basal cell carcinoma of the skin and/or carcinoma in situ of the cervix) 10. Treatment using any investigational drug within the last 28 days prior to the study 11. Any residual toxicity from prior chemotherapy (except alopecia), such as peripheral neuropathy ≥ NCI CTC v3.0 grade 2, will not be considered for treatment with oxaliplatin-containing regimens 12. History of allergy to any of the drugs in the study 13. Women of childbearing potential (\<2 years after last menstruation) or men of childbearing potential who are not using or have refused to use an effective non-hormonal contraceptive (IUD, barrier method combined with spermicidal gel or sterilization) during pregnancy and lactation 14. Unable or unwilling to comply with the study protocol 15. Presence of any other disease, dysfunction due to metastatic lesions, or suspicious medical findings that suggest a possible contraindication to the use of the study drug or that would place the patient at risk of treatment-related complications
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective Remission Rate (ORR) | Assessed up to 48 months | As assessed by the investigators using RECIST v1.1 criteria |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| R0 surgical resection rate | Assessed up to 48 months | Defined as the proportion of patients who achieved complete resection (pathologically determined R0 resection) after treatment |
| No evidence of disease rate (NED) | Assessed up to 48 months | Proportion of treated patients who achieve no evidence of disease |
| Progression Free Survival (PFS) | Assessed up to 48 months | The length of time during and after the treatment of the disease, that a patient lives with the disease without its aggravation |
| Depth of Response (DpR) | Assessed up to 48 months | The investigators evaluate the maximum tumor regression to baseline tumor ratio to determine the depth of tumor regression (DpR) and calculate the median value. |
| Recurrence Free Survival in resectable patients | Assessed up to 48 months | Defined as the time from complete resection of liver metastases or NED to the development of disease recurrence or death |
| Safety (including chemotherapy-related adverse events, catheterization-related adverse events, surgical complications, etc.) | Assessed up to 48 months | Number of patients with adverse events and severity according to NCI CTCAE v3.0 |
| Overall Survival (OS) | Assessed up to 48 months | The length of time from the start of treatment that patients diagnosed are still alive |
Countries
China
Contacts
Primary ContactLi Yuhong
Outcome results
None listed